Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021. Details are as follows:
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
William Blair Biotech Focus Conference 2021
Date: Wednesday, July 14
Panel: Developing Therapies for the Next Immuno-Oncology Targets
Time: 2:10-3:10 p.m.
Date: Thursday, July 15
Panel: Non-Viral Drug Delivery
Time: 2:00-2:45 p.m.
Live webcasts of the virtual panel discussions will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. Archived replays will be available for approximately 30 days following the events.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Investor Contact:Christopher TaylorVP, Investor Relations and Corporate CommunicationsT: 617-949-4220E: investor@codiakbio.comMedia Contact:Lindy DevereuxScient PRT: 646-515-5730E: media@codiakbio.com
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.